Art. 13 Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009…

Duration of the certificate

In forcesince 6 May 2009cited 33×
1.

The certificate shall take effect at the end of the lawful term of the basic patent for a period equal to the period which elapsed between the date on which the application for a basic patent was lodged and the date of the first authorisation to place the product on the market in the Community, reduced by a period of five years.

2.

Notwithstanding paragraph 1, the duration of the certificate may not exceed five years from the date on which it takes effect.

3.

The periods laid down in paragraphs 1 and 2 shall be extended by six months in the case where Article 36 of Regulation (EC) No 1901/2006 applies. In that case, the duration of the period laid down in paragraph 1 of this Article may be extended only once.

4.

Where a certificate is granted for a product protected by a patent which, before 2 January 1993, had its term extended or for which such extension was applied for, under national law, the term of protection to be afforded under this certificate shall be reduced by the number of years by which the term of the patent exceeds 20 years.

The 10 that are cited most themselves, of 33.

  • Judgment of the Court (Fourth Chamber), 19 July 2012. Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents.Decisioninterprets

    This reference for a preliminary ruling relates to the interpretation of, first, Articles 3 and 13(1) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection …

    19 Jul 2012 · 62011CJ0130

  • Judgment of the Court (Third Chamber), 12 December 2013. Actavis Group PTC EHF and Actavis UK Ltd v Sanofi.Decision

    In such a situation, Article 13 of Regulation No 469/2009 dictates that, upon expiry of the initial SPC, the holder thereof may no longer, in connection with the basic patent used as the basis for the grant of the SPC, oppose the marketing …

    12 Dec 2013 · 62012CJ0443

  • Judgment of the Court (Eighth Chamber) of 12 March 2015. Actavis Group PTC EHF and Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co. KDecision

    This request for a preliminary ruling concerns the interpretation of Articles 3 and 13 of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for …

    12 Mar 2015 · 62013CJ0577

  • Judgment of the Court (Grand Chamber) of 25 July 2018. Teva UK Ltd and Others v Gilead Sciences Inc.Decision

    Article 13 of that regulation, entitled ‘Duration of the [SPC]’, provides in paragraph 1 thereof as follows: ‘The [SPC] shall take effect at the end of the lawful term of the basic patent for a period equal to the period which …

    25 Jul 2018 · 62017CJ0121

  • Judgment of the Court (Third Chamber), 12 December 2013. Georgetown University v Octrooicentrum Nederland.Decision

    Moreover, Article 13 of Regulation No 469/2009 dictates that, upon expiry of such SPCs, the holder thereof may no longer, in connection with the basic patent used as the basis for the grant of those SPCs, oppose the marketing by third …

    12 Dec 2013 · 62012CJ0484

  • The Human Medicines Regulations 201258aLaw

    … medicinal product to which the application relates is entitled to a six month extension of the period referred to in Articles 13(1) and 13(3) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 …

  • The Human Medicines (Amendment etc.) (EU Exit) Regulations 201964Law

    … medicinal product to which the application relates is entitled to a six month extension of the period referred to in Articles 13(1) and 13(3) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 …

  • Order of the Court (Eighth Chamber) of 14 November 2013. Astrazeneca AB v Comptroller General of Patents, Designs and Trade Marks.Decisioninterprets

    On those grounds, the Court (Eighth Chamber) hereby rules: In the context of the European Economic Area (EEA), Article 13(1) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the …

    14 Nov 2013 · 62012CO0617

  • The Human Medicines (Amendment etc.) (EU Exit) Regulations 202047Law

    … medicinal product to which the application relates is entitled to a six month extension of the period referred to in Articles 13(1) and 13(3) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 …

  • Judgment of the Court (Grand Chamber) of 9 July 2020. Santen SAS v Directeur général de l’Institut national de la propriété industrielle.Decision

    Under Article 13 of that regulation, entitled ‘Duration of the [SPC]’: ‘1. The [SPC] shall take effect at the end of the lawful term of the basic patent for a period equal to the period which elapsed between the date on which the …

    9 Jul 2020 · 62018CJ0673